Concord Medical Schedules 2024 Annual Meeting of Shareholders

CCM 11.13.2024

Full Press ReleaseSEC FilingsOur CCM Tweets

About Gravity Analytica

Recent News

  • 01.06.2025 - Concord Medical Announces Result of 2024 Annual General Meeting
  • 12.27.2024 - Concord Medical Services Holdings Limited 2024 Annual Meeting of Shareholders
  • 12.09.2024 - Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate

Recent Filings

  • 01.06.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 01.06.2025 - EX-99.1 EX-99.1
  • 07.11.2024 - F-6 POS Post-effective amendments for immediately effective filing

BEIJING,Nov. 13, 2024/PRNewswire/ --Concord Medical Services Holdings Limited("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it will hold its 2024 annual general meeting of shareholders (the "Meeting") onDecember 27, 2024, at10:00 a.m.(Beijing Time). The meeting will be held at Room 26A1-26A5,East Tower,Hanwei Building, No.7 Guanghua Road,Chaoyang District,Beijing, China. The shareholder record date isNovember 27, 2024. A copy of the notice of Meeting is available on the Company's investor relations website athttps://ir.ccm.cn.

The purpose of the Meeting is to amend the Company's memorandum and articles of association currently in effect by the adoption of a new memorandum and articles of association to reflect the change in the ratio of its American depositary shares ("ADSs") to Class A ordinary shares, which was made effective onJuly 30, 2024. For details, please refer to the Current Report on Form 6-K filed with theSecurities and Exchange Commission("SEC") onJuly 11, 2024. The Meeting will also be convened for shareholders who are entitled to vote to discuss Company affairs with management. Concord Medical's annual report on Form 20-F filed with theSEC, containing the Company's audited financial statements for the financial year endedDecember 31, 2023, is available in the Investor Relations section of the Company's website athttp://ir.ccm.cn. The Form 20-F is also available on theSEC'swebsite athttp://www.sec.gov.

About Concord Medical

Concord Medical Services Holdings Limitedis a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals acrossChina. For more information, please seehttp://ir.ccm.cn.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

CisionView original content:https://www.prnewswire.com/news-releases/concord-medical-schedules-2024-annual-meeting-of-shareholders-302303811.html

SOURCEConcord Medical Services Holdings Limited

Concord Medical Services Holdings Limited, Investor Relations, +86 10 5903 6688, ir@ccm.cn

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com